Shots:
- Estrella reported the successful completion of its first dose cohort in the P-I/II (STARLIGHT-1) study assessing the safety, tolerability, PK, and preliminary efficacy of EB103 in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL)
- Preliminary data demonstrated a favorable safety profile, with no dose-limiting toxicities or treatment-related SAEs, based on this Data and Safety Monitoring Board has approved the initiation of second dose cohort
- In the second dose cohort, the patients will be administered with 5M receptor-positive T cells per Kg of body weight of EB103 CD19-Redirected ARTEMIS T-cell therapy
Ref: Estrella | Image: Estrella
Related News:- Akeso Reports First Patient Enrollment in P-III Study of Ivonescimab + CT to Treat Triple-Negative Breast Cancer (TNBC) in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
